5 / 12
Note:
Page 25
April 15-16, 2019 | Milan, Italy
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Joint Event on
&
PUBLIC HEALTH,
EPIDEMIOLOGY AND NUTRITION
2
nd
World Congress on
CELL AND GENE THERAPY
2
nd
International Conference on
Cell and Gene Therapy 2019 & Public Health Congress 2019
Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
HEK293-DERIVED ADENO ASSOCIATED VIRUS (AAV) PURIFICATION: COMPARI-
SON OF SMALL-SCALE LABORATORY PRODUCTION TOWARDS INDUSTRIAL FOR-
MAT USING MONOLITHS
Ales Strancar
1
, MTajnik Sbaizero
1
, L Zentilin
2
, M Leskovec
1
, B Goricar
1
, J Merkelj Koren
1
and
P Gagnon
1
1
BIA Separations, Slovenia
2
International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy
D
uring Recombinant Adeno Associated Virus (rAAV) downstream processing, a large amount of host-cell
and product related impurities needs to be removed from the product. Successful process on laboratory
scale such as Caesium chloride purification lacks scalability when the process is due to transferred to larger
industrial scale. The aim of the study was to develop robust, fast and effective rAAV virus purification platform,
which can be used for several AAV serotypes with various inserts. Lysed harvest and supernatant of rAAV9 were
first captured and concentrated on CIMmultus™ OH column, followed by intermediate step on CIMmultus™
SO3 column and further polishing on CIMmultus™ QA column. Derived purity of industrial scale monolith pu-
rification product was compared to laboratory scale purification.
Ales Strancar et al., Arch Gen Intern Med 2019, Volume 3 | DOI: 10.4066/2591-7951-C2-026
Ales Strancar is the CEO of BIA Separations and one of the main inventors of the CIM Convective Interaction Media® monolithic
columns (new generation of chromatographic support). He is author or co-author of more than 90 scientific papers dealing with
separation and purification technologies and is now one of top Slovenian Scientists. He is a co-author of five granted USA patents
and their foreign equivalents, more pending, in the field of biomolecule separations and purification. As well he is a co-author of
several book chapters dealing with novel chromatography technologies for biomolecule separation. He co-developed a number of
industrial scale purification processes among them for Octapharma, Vienna and for Boehringer Ingelheim, Vienna.
ales.strancar@biaseparations.comBIOGRAPHY